Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $21.33, for a total value of $69,322.50. Following the sale, the chief financial officer now owns 23,000 shares in the company, valued at approximately $490,590. The trade was a 12.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total value of $22,500.00.
• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $25,040.00.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded down $1.34 on Friday, hitting $18.69. The company's stock had a trading volume of 516,094 shares, compared to its average volume of 280,139. The company has a market capitalization of $915.88 million, a price-to-earnings ratio of -9.84 and a beta of 1.03. Enliven Therapeutics, Inc. has a 1 year low of $15.96 and a 1 year high of $30.03. The firm has a fifty day moving average price of $21.03 and a 200-day moving average price of $23.62.

Remove Ads

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a "buy" rating and a $42.00 target price on the stock. HC Wainwright raised their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $38.75.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Enliven Therapeutics during the 4th quarter worth approximately $97,000. BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $112,000. ExodusPoint Capital Management LP acquired a new position in shares of Enliven Therapeutics during the fourth quarter valued at approximately $200,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at approximately $228,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.